These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34356066)

  • 21. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Bhaskaran SP; Chandratre K; Gupta H; Zhang L; Wang X; Cui J; Kim YC; Sinha S; Jiang L; Lu B; Wu X; Qin Z; Huang T; Wang SM
    Int J Cancer; 2019 Aug; 145(4):962-973. PubMed ID: 30702160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
    Negura L; Uhrhammer N; Negura A; Artenie V; Carasevici E; Bignon YJ
    Fam Cancer; 2010 Dec; 9(4):519-23. PubMed ID: 20567915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.
    Pallonen TA; Lempiäinen SMM; Joutsiniemi TK; Aaltonen RI; Pohjola PE; Kankuri-Tammilehto MK
    Sci Rep; 2022 Apr; 12(1):6704. PubMed ID: 35469032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
    Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
    Kang E; Seong MW; Park SK; Lee JW; Lee J; Kim LS; Lee JE; Kim SY; Jeong J; Han SA; Kim SW;
    Breast Cancer Res Treat; 2015 May; 151(1):157-68. PubMed ID: 25863477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Lavoro A; Scalisi A; Candido S; Zanghì GN; Rizzo R; Gattuso G; Caruso G; Libra M; Falzone L
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35383859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
    Kwiatkowski F; Arbre M; Bidet Y; Laquet C; Uhrhammer N; Bignon YJ
    PLoS One; 2015; 10(6):e0127363. PubMed ID: 26047126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
    Nielsen HR; Nilbert M; Petersen J; Ladelund S; Thomassen M; Pedersen IS; Hansen TV; Skytte AB; Borg Å; Therkildsen C
    Fam Cancer; 2016 Oct; 15(4):507-12. PubMed ID: 26833046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
    Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical aspects of familial ovarian cancer - current status and issues in Japan].
    Sekine M; Yoshihara K; Tanaka K
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):506-11. PubMed ID: 22504673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
    Sowter HM; Ashworth A
    Carcinogenesis; 2005 Oct; 26(10):1651-6. PubMed ID: 15917310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
    Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.